RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $570 to $576.
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $570 to $576.